ONCS - OncoSec Medical - Stock Forecast

Biotechnology & Medical Research - Industry

Coverage Performance Price Targets & Ratings Chart Insider Trading

with an average price target of $209.44. This is a potential upside of $209.44 (0%) from yesterday's end of day stock price of $0.

OncoSec Medical's activity chart (see below) currently has 2 price targets and 4 ratings on display.

Stock Analyst Price Targets - Review

Most recent stock forecast was given by JASON KOLBERT from DAWSON JAMES on 17-Mar-2022.

Best performing analysts who are covering ONCS - OncoSec Medical:

Edward Tenthoff Jason Kolbert Kaveri Pohlman

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jason Kolbert (DAWSON JAMES)

Buy

220

2 years 1 months 2 days ago

0/1 (0%)

$147.4 (203.03%)

Please subscribe to see the analyst performance score

Edward Tenthoff (PIPER SANDLER)

Buy

660

4 years 6 months 9 days ago

0/1 (0%)

$480.92 (268.55%)

Please subscribe to see the analyst performance score

Kaveri Pohlman (BTIG)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is ONCS (OncoSec Medical) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on ONCS (OncoSec Medical) with a proven track record?

EDWARD TENTHOFF

Which analyst has the current lower performing score on ONCS (OncoSec Medical) with a proven track record?

KAVERI POHLMAN

Which analyst has the most public recommendations on ONCS (OncoSec Medical)?

Edward Tenthoff works at PIPER SANDLER and has 7 price targets and 7 ratings on ONCS

Which analyst is the currently most bullish on ONCS (OncoSec Medical)?

Kaveri Pohlman with highest potential upside - $0

Which analyst is the currently most reserved on ONCS (OncoSec Medical)?

Edward Tenthoff with lowest potential downside - -$0